RxDoctor Payments Data

Crystal Chick, NP

Nurse Practitioner · Albuquerque, NMNPI 1285285395

Payments from drug & device makers

$668in general payments, 2019–2025

Across 16 payments — averaging $41.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$123
  • AstraZeneca$122
  • Shionogi Inc$121
  • Lilly USA, LLC$111
  • Astellas Pharma US Inc$88
  • Boehringer Ingelheim$33
  • plus $71 from 3 others

What the payments were for

  • Food & beverage$668100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$668 in reported general payments places this provider in the 80th percentile of 624 nurse practitioner providers in New Mexico.

See all nurse practitioner providers in New Mexico

Medicare billing

Part B allowed, 2024
$31,923
Medicare patients
164
Services billed
1,690

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$92,754
JardianceEmpagliflozin36$58,134
MounjaroTirzepatide41$43,635
TrulicityDulaglutide31$35,363
JanuviaSitagliptin Phosphate24$31,736
FarxigaDapagliflozin Propanediol19$30,507
MyrbetriqMirabegron17$20,977
XareltoRivaroxaban21$20,309
EliquisApixaban15$16,905
Fluticasone Propionate HfaFluticasone Propionate12$4,502
SymbicortBudesonide/Formoterol Fumarate17$3,477
Gabapentin190$3,004
Aripiprazole16$2,829
Levothyroxine Sodium243$2,804
Atorvastatin Calcium154$2,376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$123$92,75484 claims
Lilly USA, LLCMounjaro, Trulicity$111$78,99872 claims
Boehringer IngelheimJardiance$33$58,13436 claims
AstraZenecaFarxiga, Symbicort$122$33,98436 claims
Astellas Pharma US IncMyrbetriq$88$20,97717 claims
Johnson & JohnsonXarelto$26$20,30921 claims
AbbVieSynthroid$14$80319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 624 nurse practitioner providers in New Mexico.

Other nurse practitioner in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →